Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects
Clinical trial NCT02073812 · COMPLETED
Trial details
- NCT number
- NCT02073812
- Sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-01
- Primary completion
- 2014-04-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.